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Sixty percent of all pregnancies worldwide occur in malaria endemic regions. Pregnant
women are at greater risk of malaria infection than their non-pregnant counterparts and
have a higher risk of adverse birth outcomes including low birth weight resulting from
intrauterine growth restriction and/or preterm birth. The complement system plays an
essential role in placental and fetal development as well as the host innate immune
response to malaria infection. Excessive or dysregulated complement activation has
been associated with the pathobiology of severe malaria and with poor pregnancy
outcomes, dependent and independent of infection. Here we review the role of
complement in malaria and pregnancy and discuss its part in mediating altered placental
angiogenesis, malaria-induced adverse birth outcomes, and disruptions to the in
utero environment with possible consequences on fetal neurodevelopment. A detailed
understanding of the mechanisms underlying adverse birth outcomes, and the impact of
maternal malaria infection on fetal neurodevelopment, may lead to biomarkers to identify
at-risk pregnancies and novel therapeutic interventions to prevent these complications.
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THE GLOBAL BURDEN OF MALARIA
Nearly half of the world’s population remains at risk of malaria infection (WHO, 2013).
Malaria is caused by the protozoan parasite Plasmodium and includes ﬁve species that infect
humans: Plasmodium falciparum, P. vivax, P. ovale, P. malaria, and P. knowlesi. Among these,
P. falciparum causes the most severe disease and accounts for the majority of malaria-associated
deaths (Dellicour et al., 2010). Pregnant women are particularly susceptible to malaria-associated
morbidity and mortality with approximately 125 million pregnancies at risk of infection each
year (Dellicour et al., 2010). Malaria during pregnancy can result in anemia, stillbirth, and
low birth weight (LBW) resulting from intrauterine growth restriction (IUGR) and/or preterm
birth (PTB; Rogerson et al., 2003; Umbers et al., 2011; Eisele et al., 2012). These outcomes
are associated with an increased risk of neonatal mortality and contribute to an estimated
200 000 infant deaths annually (Steketee et al., 2001; van Geertruyden et al., 2004). PTB,
IUGR, and LBW have consistently been associated with developmental delay and an increased
risk of long-term health consequences including cardiovascular disease, diabetes, and obesity
(March of Dimes, PMNCH, Save the Children, WHO, 2012; Visentin et al., 2014). Further, a
growing body of evidence has linked in utero exposure to infections to long-term cognitive
and behavioral disorders including autism, schizophrenia, and depression (Knuesel et al.,
2014). Despite the connection between prenatal infections and adverse neurological outcomes
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for the developing child, the potential impact of in utero
exposure to malaria on subsequent neurodevelopment remains
understudied.
PATHOPHYSIOLOGY OF PLACENTAL
MALARIA
Plasmodium falciparum infection during pregnancy can result
in placental malaria (PM), deﬁned by the accumulation of
parasitized erythrocytes (PEs) in the placental intervillous
space and the inﬁltration of maternal monocytes/macrophages
(Rogerson et al., 2003). The PEs that sequester in the placenta
bind via a unique P. falciparum erythrocyte membrane protein
1 (PfEMP1) variant, VAR2CSA, to the glycosaminoglycan
chondroitin sulfate A (CSA) that is expressed on the
syncytiotrophoblast lining of the intervillous space (Duﬀy
et al., 2006; Mens et al., 2010; Clausen et al., 2012). As such,
protective immunity developed during exposure to malaria
in non-pregnancy is ineﬀective such that primigravidae are
at highest risk of PM and its associated poor birth outcomes
(Desai et al., 2007). Adaptive immunity is gradually acquired
during malaria infections in pregnancy and is mediated by the
acquisition of anti-VAR2CSA adhesion blocking and opsonic
antibodies (Fried et al., 1998; Desai et al., 2007; Keen et al., 2007).
Sequestration of PEs stimulates maternal macrophages to
express β-chemokines, including monocyte chemotactic protein-
1 (MCP-1), macrophage inﬂammatory protein (MIP)-1α, and
MIP-1β, that recruit other inﬂammatory mediators and initiate
the inﬂammatory cascade (Suguitan et al., 2003). This localized
placental immune response and inﬂammation is thought to
contribute to the adverse birth outcomes associated with PM.
Although the precise mechanisms of placental and fetal injury are
unclear, evidence suggests that the complement system may play
a role.
THE COMPLEMENT SYSTEM
The complement system is a crucial immune surveillance and
innate defense pathway. It is composed of both soluble and
membrane bound proteins that cooperate to function in host
defense and inﬂammation. Normally, the complement system
is maintained at a basal level of activation but can be further
ampliﬁed through three major activation pathways: the classical
pathway, the mannose-binding lectin (MBL) pathway, and the
alternative pathway (Ricklin et al., 2010; Wagner and Frank,
2010; Woodruﬀ et al., 2011). The classical pathway is activated
by binding of C1q to IgM or IgG immune complexes, the
mannose-binding lectin pathway is activated by binding of
foreign carbohydrate moieties, and the alternative pathway is
activated by bacterial lipopolysaccharide (LPS) and negatively
charged viral surfaces. The three pathways converge in a
sequential cleavage cascade that results in opsonization-mediated
phagocytosis, cell lysis, or an inﬂammatory response through the
activation of the C3-convertase, which catalyzes the cleavage of
C3 to C3a and C3b. C3b is an opsonizing fragment that binds
to foreign antigens and increases phagocytosis. In addition, C3b
can combine with C3-convertases to form the C5-convertase
which cleaves C5 to C5a and C5b. C3a and C5a are potent
anaphylatoxins that activate neutrophils and macrophages to
promote inﬂammation. C5b recruits C6–C9 and forms the
membrane attack complex (MAC), which can insert in cell
membranes and lyse target cells. In addition to these traditional
pathways, direct C3 and C5 cleavage can occur via thrombin or
serine proteases (Huber-Lang et al., 2002; Ward, 2004; Huber-
Lang et al., 2006).
The complement system is also an important regulator
of several developmental processes, and as such requires
tight regulation to prevent excessive activation (Ricklin
and Lambris, 2007; Silver et al., 2010). Regulation is
controlled through the expression of complement regulatory
proteins including the complement receptor 1 (CR1),
decay accelerating factor (DAF), and Factor H. These
proteins control complement activation by binding eﬀector
proteins to limit activation or to accelerate degradation
of complement components (Ricklin et al., 2010). The
important role of complement in normal developmental
processes is highlighted by several diseases that are linked to
mutations in complement eﬀector and regulatory proteins
including, systemic lupus erythematosus, age-related macular
degeneration, atypical hemolytic uremic syndrome (aHUS),
paroxysmal nocturnal hemoglobinuria (PNH), and deﬁcits
in vascular development and metabolism (Seelen et al., 2003;
Edwards et al., 2005; Haines et al., 2005; Klein et al., 2005;
Risitano, 2012; Coﬁell et al., 2015; Martinez-Barricarte et al.,
2015).
COMPLEMENT ACTIVATION IN
PREGNANCY AND OBSTETRIC
COMPLICATIONS
The complement system plays an essential role in healthy
pregnancies (Regal et al., 2015) protecting against local infection
and regulating the maternal immune response to the semi-
allogenic fetal tissue (Richani et al., 2005; Derzsy et al., 2010).
During early pregnancy the trophoblast layer invades the
decidua resulting in an inﬂammatory response controlled by
trophoblast-derived complement regulatory proteins including
membrane cofactor protein (MCP, CD46), protectin (CD59),
and DAF (CD55; Tedesco et al., 1993). The placenta synthesizes
complement components, providing a local source of protection
from infection. Histological studies have reported positive
staining for C1q, C9, C3d, C4BP, and Factor H in placentas
from healthy term pregnancies. Human trophoblast cells
secrete C3 and C4 proteins and phagocytic activity in the
trophoblast is mediated by activated C3 in mouse trophoblast
cells (Albieri et al., 1999; Bulla et al., 2009). Endothelial
cells in the placenta secrete C1q, which appears at sites of
trophoblast invasion into the decidual tissue (Bulla et al., 2008).
Throughout pregnancy regulatory proteins produced by the
chorion facilitate complement activity and prevent complement-
mediated placental injury.
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Excessive or dysregulated activation of the complement
system can overwhelm these regulatory and protective
pathways. Multiple studies have reported an association
between complement split products (e.g., C3a and C5a) or
mutations in complement regulatory proteins and obstetric
complications (Tedesco et al., 1993; Lynch et al., 2011; Denny
et al., 2013). An estimated 8–18% of women with preeclampsia
have mutations in complement regulatory proteins (Salmon
et al., 2011). Increased circulating levels of C5a, activated
Factor B (Bb), C5b-9 and C3a/C3 ratio in pregnancy have
been linked to spontaneous abortion, preeclampsia, hemolysis,
and the elevated liver enzymes, low platelet count (HELLP)
syndrome (Girardi et al., 2006a; Derzsy et al., 2010; Lynch and
Salmon, 2010). Experimental models have provided mechanistic
evidence that blockade of C5a, C5a receptor (C5aR), Factor
B, C3, or C6 in non-infection models protects against fetal
lethality and IUGR (Holers et al., 2002; Girardi et al., 2006b;
Lynch et al., 2011; Singh et al., 2011). C5a may contribute
to multiple complications in pregnancy via its ability to
synergistically induce the secretion of pro-inﬂammatory (e.g.,
TNF, IL-8, IL-1β) and anti-angiogenic factors (e.g., soluble
fms-like tyrosine kinase-1 [sFlt-1]) from leukocyte populations
(Conroy et al., 2009; Langer et al., 2010). Cleavage of C5 has
also been reported to induce monocyte recruitment, matrix
metalloprotease production, and cervical ripening in a mouse
model of LPS-induced PTB (Gonzalez et al., 2011, 2013). In this
model, blocking C5a-C5aR signaling rescued oﬀspring from
cortical fetal brain injury (Pedroni et al., 2014). Finally, sC5b-9
in urine has been associated with an anti-angiogenic proﬁle
including elevated sFlt-1, and reduced placental growth factor
(PGF) and vascular endothelial growth factor (VEGF; Guseh
et al., 2015).
COMPLEMENT IN PLACENTAL MALARIA
Complement is a key component of the innate immune
response to malaria and contributes to both protection
(e.g., PE opsonization) and pathologic host responses (e.g.,
coagulopathy, inﬂammation, and endothelial activation; Silver
et al., 2010; Biryukov and Stoute, 2014). Activation can occur
by both traditional and non-traditional pathways (Figure 1).
For example, IgG has been shown to be deposited on the
surface of PEs and C-reactive protein has been shown to
be elevated in malaria infection (Mibei et al., 2005), both of
which can activate the classical pathway. Activation of the
alternative pathway can occur from parasite-induced alterations
to the erythrocyte surface that induce spontaneous C3 activation
or by platelet-derived factor D following vascular damage
(Roestenberg et al., 2007). Evidence for MBL pathway activation
is inferred from a higher prevalence of MBL polymorphisms
(e.g., MBL2.LXPA haplotype) in women with PM, however,
no association was observed between levels of MBL and
infection or birth outcomes (Thevenon et al., 2009). Finally,
malaria can activate complement through C3-independent
pathways through cleavage of C3 and C5 via thrombin
and serine proteases released by phagocytic leukocytes or
the parasite (Huber-Lang et al., 2002, 2006; Conroy et al.,
2009).
This excessive complement activation during malaria
infection can perturb the tight regulation that is important
during a healthy pregnancy. Research in human populations
and mouse models support the hypothesis that malaria-induced
complement activation contributes to adverse birth outcomes by
increasing inﬂammation and dysregulating angiogenic processes
essential for normal placental development and function
(Conroy et al., 2011, 2013). Several observational studies have
reported elevated C5a in peripheral and placental blood in
women with PM and linked these changes to adverse birth
outcomes, including IUGR, PTB, and LBW (Conroy et al., 2011).
Further, this was associated with dysregulated angiogenesis in
the placenta (Conroy et al., 2009, 2013). Placental and fetal
vascular development is regulated by several pathways, most
notably the VEGF and Angiopoietin-Tie2 pathways (Geva
et al., 2002; Charnock-Jones et al., 2004; Burton et al., 2009).
The VEGF axis is essential for placental vascularization, vessel
growth, and remodeling (Kingdom et al., 2000; Charnock-
Jones et al., 2004; Kaufmann et al., 2004). VEGF and other
pro-angiogenic factors in this family, such as PGF, interact with
anti-angiogenic mediators (e.g., sFlt-1) to regulate endothelial
cell survival, proliferation, migration, and sprouting (Demir
et al., 2004, 2006). Malaria-induced complement activation may
result in a shift to an anti-angiogenic proﬁle (i.e., increased
sFlt-1 and decreased PGF and VEGF) that can impede normal
vasculogenic and angiogenic processes (Silver et al., 2011;
Conroy et al., 2013). In vitro, C5a, in combination with parasite
products, results in the synergistic release of pro-inﬂammatory
mediators and anti-angiogenic factors, including sFlt-1, from
human monocytes (Conroy et al., 2009). Complement-induced
anti-angiogenic activity can disrupt these closely regulated
processes and provoke changes in the placental vasculature.
Genetic and pharmacological blockade of C5a-C5aR increases
placental vascular length and segment number, reduces vascular
resistance in the placenta, and increases fetal weight and
viability (Conroy et al., 2013). This rescue is thought to be
mediated in part by reducing the impact of C5a on the Ang/Tie2
pathway.
The angiopoietins, Ang-1 and Ang-2, are angiogenic factors
that act in a context-dependent manner with VEGF to
regulate placental vasculogenesis, angiogenesis, and vascular
inﬂammation. The angiopoietins competitively bind to the Tie-
2 receptor and act as antagonists to one another with Ang-1
inducing vascular maturation and Ang-2 causing destabilization
of the vascular network and angiogenesis (Charnock-Jones et al.,
2004). Decreased levels of circulating Ang-1 and elevated levels
of Ang-2 were observed in malaria-infected pregnant women in
Cameroon and Malawi (Silver et al., 2011; Conroy et al., 2013).
Further, an increase in the ratio of Ang-2/Ang-1 was observed in
Cameroonian women who delivered LBW infants and this eﬀect
was recapitulated in the mouse model of PM (Silver et al., 2010).
These ﬁndings support the role of dysregulated angiogenesis
in adverse birth outcomes associated with PM and highlight
the potential for Ang/Tie2-targeted therapies as intervention
strategies.
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FIGURE 1 | Overview of key pathways in placental malaria (PM) and potential targets for therapeutic intervention to improve birth outcomes.
Strategies to optimize placental vascular development and function may impact the length of gestation, birth weight, and birth outcome by targeting complement
and complement-associated pathways. Inflammation and dysregulation of angiogenic pathways has been observed in association with chondroitin sulfate A
(CSA)-binding parasitized erythrocytes (PEs) in the intervillous space of the placenta. Key angiogenic factors such as (1) the angiopoietins (Ang), Ang-1 and Ang-2,
which act as antagonists at the Tie-2 receptor and (2) vascular endothelial growth factor (VEGF), mediate vasculogenic and angiogenic processes in the placenta.
(3) Malaria-induced complement activation resulting in the cleavage of C5a, a potent anaphylatoxin, contributes to increased inflammation and dysregulated
angiogenesis and can be targeted via anti-C5a antibodies or alternatively, by more cost-effective strategies such as (4) L-arginine supplementation. L-arginine
supplementation could increase bioavailable nitric oxide (NO), which acts to reduce malaria-induced inflammation at the maternal-fetal interface and promote
vascular development. ICAM, intercellular adhesion molecule; MAC, membrane attack complex; VWF, von Willebrand factor.
POTENTIAL THERAPEUTIC STRATEGIES
TARGETING COMPLEMENT AND
ASSOCIATED PATHWAYS
Optimizing placental vascular development and function and
resulting changes in the in utero environment can impact the
length of gestation, birth weight, and birth outcome. PTB is now
the leading direct cause of infant mortality and the second leading
cause of death in children under the age of ﬁve, after pneumonia
(Blencowe et al., 2012; March of Dimes, PMNCH, Save the
Children, WHO, 2012). Maternal infections are considered the
major modiﬁable factor contributing to PTB, with the highest
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burden occurring in low resource settings. Despite the enormous
public health impact of malaria in pregnancy, there are few
eﬀective interventions, and even fewer aimed at promoting
healthy placental development. The above pathways highlight key
angiogenic mediators (e.g., Ang/Tie2 and VEGF) altered during
PM that can be investigated as targets for new interventions to
improve birth outcomes in high-risk pregnancies (Figure 1).
Angiogenic-modifying compounds are currently being
investigated therapeutically for a number of diseases, including
anti-angiogenic therapies for metastatic cancer, wound healing,
and pathological vasculopathies and retinopathies (Huang et al.,
2010; Wietecha and DiPietro, 2013; Gacche and Meshram, 2014).
Historically, most approaches have targeted VEGF to either
restrict (anti-VEGF therapy as cancer therapeutics) or promote
(VEGF therapy in wound healing) angiogenesis (Delli Carpini
et al., 2010; Wietecha and DiPietro, 2013). Although early
clinical trials yielded promising results in tumor stabilization
and improved patient survival, resistance to VEGF-targeted
therapies is emerging (Bergers and Hanahan, 2008; Ebos et al.,
2009). Only recently has the Ang/Tie2 pathway been targeted for
regulating angiogenesis. In cancer therapies, Tie2 inhibitors and
Ang-1/-2 traps have been investigated and have shown promising
anti-tumor growth activity in various cancer cell lines and good
tolerability in early human trials (Huang et al., 2010).
Ang/Tie-2-targeted therapeutics have not been investigated in
the context of PM, however, in vivo data using the mouse model
of cerebral malaria have shown potential utility (Serghides et al.,
2014). While this has yet to be evaluated in humans, it provides
proof-of-principle evidence to support the use of Ang-targeted
therapies. Given the observed decrease in circulating maternal
Ang-1 and the associated dysregulated placental angiogenesis,
therapies that regulate the Ang/Tie2 pathway may have clinical
use in PM but there are important safety barriers to overcome
with any of these agents.
A humanized monoclonal antibody to complement C5,
Eculizumab, is approved to treat aHUS and PNH (Risitano,
2012). aHUS shares many pathophysiological features with
malaria including release of free heme, complement activation,
and endothelial dysfunction in association with the release of
vWF andAng-2 (Noris et al., 2014). PNH is caused by the reduced
expression of complement regulatory proteins on hematopoietic
cells resulting in intravascular hemolysis, thrombophilia, and
cytopenias. During pregnancy, patients with PNH are at a greater
risk of mortality (Ray et al., 2000). Case reports of Eculizumab
for PNH during pregnancy suggest that blockade of C5 signaling
does not negatively impact birth outcomes (Kelly et al., 2010;
Marasca et al., 2010; Patriquin and Leber, 2015). Given that
complement is an upstream regulator of angiogenesis and the
trials of anti-C5 antibody in pregnancy report good tolerability,
the use of anti-complement strategies to treat PM is promising
(Figure 1). However, the high cost of anti-complement antibodies
would limit its use in resource-constrained settings and therefore
more aﬀordable strategies need to be explored. For example, L-
arginine is an essential amino acid in pregnancy and immediate
precursor of nitric oxide (NO), an endogenous regulator of
placental vascular development (Goodrum et al., 2003; Krause
et al., 2011). There is substantial evidence that malaria-infection
depletes L-arginine and greatly reduces bioavailable NO and
that this contributes to the pathobiology of severe malaria
(Anstey et al., 1996; Lopansri et al., 2003; Serghides et al.,
2011; Weinberg et al., 2014). Low dietary intake of L-arginine
is common in resource-constrained settings and further depletes
bioavailable NO. L-arginine supplementation in pregnancy
may promote placental vascular development and function by
restoring bioavailable NO (Figure 1). Intervention strategies
targeting the L-arginine-NO pathway are being discussed as
potential therapeutics for preeclampsia and appear promising
due to simple routes of administration, low cost, and a very
low toxicity proﬁle in pregnancy (Cindrova-Davies, 2014; Johal
et al., 2014). Given the number of pregnancies at risk of malaria
infection, in combination with the rising rates of PTB particularly
in low resource settings, L-arginine supplementation may present
a safe, aﬀordable, and feasible intervention to reduce malaria
immunopathology and protect the in utero environment.
THE IMPACT OF MALARIA ON
NEUROCOGNITIVE DEVELOPMENT OF
OFFSPRING
It is well established that normal placental development is
fundamental to optimal fetal growth. In addition to PM-
induced changes in vascular development, malaria infection
may interfere with complement-mediated pathways that regulate
neurodevelopment in utero (Figure 2). Research has highlighted
the pivotal role that the prenatal environment plays in postnatal
neurodevelopment as well as later life cognition and behavior
(Bilbo and Schwarz, 2009; Bale et al., 2010; Mwaniki et al.,
2012). The impact of prenatal infection on neurodevelopmental
processes has been examined in animal models and in children
(Deverman and Patterson, 2009; Khandaker et al., 2012).
Maternal viral and bacterial infections have been linked to
increased risk of developmental delay, schizophrenia, autism,
bipolar disease, and paraventricular leukomalacia (Ellman and
Susser, 2009; Parboosing et al., 2013). However, to date little
is known about the role of maternal malaria infection on
in utero neurodevelopment. It is estimated that 200 million
children under the age of ﬁve in low and middle-resource
settings are not reaching their developmental potential as a
result of exposure to environmental factors that negatively impact
early neurocognitive development, including a prominent role
for malaria infection (Grantham-McGregor et al., 2007). The
complement system may be a common pathway involved in the
regulation of healthy placental and fetal development as well as in
utero neurodevelopmental processes.
Most complement components and receptors are expressed
by astrocytes, microglia and neurons in the CNS (O’Barr
et al., 2001; Veerhuis et al., 2011) and the role of the
complement system in neurodegenerative processes has been
well studied (Bonifati and Kishore, 2007; Woodruﬀ et al.,
2011; Orsini et al., 2014). Complement activation has been
linked to neuro-inﬂammation in several neurodegenerative
disorders including stroke, Parkinson’s disease, and Alzheimer’s
disease (Zanjani et al., 2005; Banz and Rieben, 2012; Pavlovski
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FIGURE 2 | Proposed mechanism of PM-mediated adverse birth outcomes and altered neurodevelopmental processes. PM is characterized by
sequestration of PEs in the intervillous space of the placenta resulting in the recruitment of leukocytes (monocytes and macrophages), complement activation, and
localized inflammation (A). We propose that this localized maternal inflammation induces an inflammatory and complement response in the fetus (B). Subsequently,
induced complement activation and dysregulation of complement effector and regulatory proteins impact neurodevelopmental processes by altering brain cytokine
levels, dysregulating angiogenic processes, and altering normal synaptic pruning (C). Initiation of the complement cascade induces maternal inflammation which can
result in the presence of inflammatory mediators in the fetal brain. Complement may also impact fetal cerebral vascular development and dependent
neurodevelopmental pathways. Finally, increased levels of complement can lead to excessive elimination of synapses and disrupt refinement of precise neural circuits
that are critical to normal fetal neurodevelopment. Adapted from McDonald et al. (2013) Trends in Parasitology 29(5) 213–219. Adapted with permission.
et al., 2012). Complement-mediated recruitment and activation
of glial cells, which secrete cytokines and free radicals, can
disrupt neuronal function and induce neurotoxicity (Zanjani
et al., 2005; Ager et al., 2010). While any speciﬁc role of
the complement system in fetal neurodevelopmental processes
remains unknown, it has recently been linked with numerous
early neurodevelopmental processes including neurogenesis,
cell migration, and synaptic pruning (Rahpeymai et al., 2006;
Chu et al., 2010; Stephan et al., 2012; Pedroni et al.,
2014).
Research in our laboratory using a mouse model of PM,
has observed impaired learning and memory, and increased
depressive-like behavior in oﬀspring born to malaria-infected
dams. This correlated with reduced regional levels of major
biogenic amines (dopamine, serotonin and norepinephrine) in
the frontal cortex, temporoparietal cortex, and the striatum.
The behavioral phenotype and reduction in circulating levels of
neurotransmitters was rescued by genetic and pharmacological
blockade of signaling via the C5a-C5aR pathway (McDonald
et al., 2015). Importantly, these results were observed
independent of a birth phenotype (LBW or PTB). In the absence
of infection-induced LBW, the inﬂammatory pathways induced
by maternal infection can result in a fetal inﬂammatory response,
altered angiogenesis, and changes in synaptic development that
can impact in utero and postnatal neurodevelopmental processes
(Figure 2). While the speciﬁc role that the complement system
plays in fetal neurodevelopment continues to be elucidated,
this research has important implications for malaria as many
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exposed pregnancies do not result in a birth phenotype but may
still be at risk of adverse neurodevelopmental outcomes.
CONCLUSION
The majority of all pregnancies worldwide are at risk of
malaria infection (Dellicour et al., 2010). These pregnancies
occur in low resource settings where the burden of adverse
birth outcomes is greatest. Based on the fundamental role
the complement system plays in the regulation of immune,
vascular and central nervous system development, we
propose that the complement system plays a central role
in the pathology, adverse birth outcomes, and potential
neurocognitive impairments resulting from malaria infection
in pregnancy.
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